The 9th International conference on leukemia and Hematologic Oncology convoked by Conference Series LLC during October 05-06, 2017 was successfully held at London,UK with a theme “Exploring latest Innovations and Interactive discussions on Leukemia and Hematologic Oncology care” was a great success where eminent keynote speakers from various reputed institutions with their resplendent presence addressed the gathering.

Thanks to all our momentous speakers, conference attendees who contributed towards the successful run of the conference.

Hematologic Oncology 2017 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the fields of Leukemia, Hematologic Oncology, Haematology, Paediatric and Hematologic Oncology.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

· Leukemia

· Hemotology

· Hematologic-oncology

· Pediatric Hematology

· Hematology nursing

· Hematology Market

· Veterinary Hematology

· Blood Disorders and Blood oncology

· Leukemia immunology

· Hemato Immunology &Stem Cell Research

· Cancer and Alternative Medicine

· Haematological malignancies

· Haematological malignancies: Prognosis

· Biomarkers

· Bone Marrow Transplantation and surgery

· Advance in Bone Marrow Transplantation

Hematologic Oncology 2017 Organizing Committee would like to thank the Moderator of the conference, Jan Jacques Michiels, Goodheart Institute & Foundation in Nature Medicine & Health,Netherlands, who has contributed a lot for the smooth functioning of this event.

Our special thanks to David J Bearss, Tolero Pharmaceuticals, USA for his special participation as Key Note Speaker titled “Targeting MCL1-dependant cancers by CDK9 inhibition” which marked the special attraction at the conference.

Our special thanks to Steven L. Warner, Tolero Pharmaceuticals, USA for his special participation as Key Note Speaker titled “Targeting novel kinases in hematological malignancies” which marked the special attraction at the conference.

Our special thanks to Jan Jacques Michiels, Goodheart Institute, Netherlands  for his special participation as Key Note Speaker titled “Sticky platelet syndrome and MPN disease burden in JAK2 Thrombocythemia and Polycythemia Vera, and in JAK2, MPL and CALR Thrombocythemias: Implications for novel non-leukemogenic treatment options in prefibrotic Myeloproliferative Neoplasms anno 2018” which marked the special attraction at the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following topics were highlighted as Symposium and Special sessions:

Extension of 2016 World Health Organization (WHO) classification into a new set of clinical, laboratory, molecular, and pathological criteria for the diagnosis of myeloproliferative neoplasms: from Dameshek to Vainchenker, Green and Kralovics- Jan Jacques Michiels, Goodheart Institute, Netherlands

Variations in ALL responses to Daunorubicin exist independently of genetic variation in the ATM gene - Hussain M Al-Aamri, Latrobe Univesity, Australia.

Clinicopathological study of coagulation profile in non-haematological malignancies - Sushma belurkar, Manipal University, India

Conference Series LLC is privileged to felicitate Hematologic Oncology 2017 Organizing Committee, Chairs & Co-Chairs who supported for the success of this event. Conference Series LLC would like to thank every individual participant for the enormous exquisite response. This inspires us to continue organizing events and conferences for further research in the field of Hematologic Oncology.

With the valuable feedback received from the participants of Hematologic Oncology 2016,Conference Series LLC is glad to announce the commencement of “International conference on leukemia and Hematologic Oncology  during October 22-23, 2018 Warsaw, Poland. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of managing Leukemia and Hematologic Oncology and its concomitant risk factors.

Let us meet again @ Hematologic Oncology 2018